A joint venture cell and gene therapy company set up by UK-based Avacta Group Plc and South Korea’s Daewoong Pharmaceutical Co Ltd has closed a Series A financing of $7.3 million to further develop its pipeline of advanced therapies. The venture, AffyXell Therapeutics, was established in 2020 and is located in South Korea.
